Abstract Objective Depo-Provera® is a contraceptive approved by the US Food and Drug
Administration (FDA) since 1992 and used worldwide by more than 90 million women. Aim …

Background and objective: The COVID-19 pandemic has reduced the ability of young
people to access appropriate and timely sexual and reproductive healthcare (SRH). The aim …

Environmental progestins are implicated in endocrine disruption in vertebrates. Additional
targets that may be affected in organisms are poorly known. Here we report that …

Medroxyprogesterone acetate (MPA) is widely known for its use in combination hormone
therapy for postmenopausal women. However, MPA is also commonly used in young …

To facilitate an integrated and rational approach to the care of women with epilepsy of
childbearing potential, a group of experts appointed by Italian scientific societies in the fields …

Background: Bone mineral density (BMD) loss among depot medroxyprogesterone acetate
(DMPA) users is a controversial issue. Aspects under debate include whether the number of …

This pathophysiology text offers a unique conceptual approach that facilitates learning by
viewing pathophysiology as health care professionals do. Students will learn about general …

Introduction and literature review Contraceptive prevalence rate in Kenya is at 58% as per
the 2014 Kenya Demographic Health Survey. Several factors lead to discontinuation and …

Introducción: Atendiendo al desarrollo que ha alcanzado Cuba en la atención prenatal se
requiere de un programa de atención nacional estandarizado y basado en la evidencia …

The United States Food and Drug Administration (FDA) announced on 17 November 2004
that a black box warning would be added to the labelling of depot medroxyprogesterone …